AU2008305303A1 - Methods and compounds for treating retinol-related diseases - Google Patents

Methods and compounds for treating retinol-related diseases Download PDF

Info

Publication number
AU2008305303A1
AU2008305303A1 AU2008305303A AU2008305303A AU2008305303A1 AU 2008305303 A1 AU2008305303 A1 AU 2008305303A1 AU 2008305303 A AU2008305303 A AU 2008305303A AU 2008305303 A AU2008305303 A AU 2008305303A AU 2008305303 A1 AU2008305303 A1 AU 2008305303A1
Authority
AU
Australia
Prior art keywords
alkyl
formula
compound
optionally substituted
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008305303A
Other languages
English (en)
Inventor
Tam V. Bui
Mustapha Haddach
Nathan L. Mata
Kim B. Phan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revision Therapeutics Inc
Original Assignee
Revision Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revision Therapeutics Inc filed Critical Revision Therapeutics Inc
Publication of AU2008305303A1 publication Critical patent/AU2008305303A1/en
Assigned to REVISION THERAPEUTICS, INC. reassignment REVISION THERAPEUTICS, INC. Request for Assignment Assignors: SIRION THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2008305303A 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases Abandoned AU2008305303A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97576507P 2007-09-27 2007-09-27
US60/975,765 2007-09-27
US98132207P 2007-10-19 2007-10-19
US60/981,322 2007-10-19
PCT/US2008/076499 WO2009042444A2 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases

Publications (1)

Publication Number Publication Date
AU2008305303A1 true AU2008305303A1 (en) 2009-04-02

Family

ID=40512081

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008305303A Abandoned AU2008305303A1 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases

Country Status (8)

Country Link
EP (1) EP2205234A4 (https=)
JP (1) JP2010540541A (https=)
KR (1) KR20100097098A (https=)
CN (1) CN101873852A (https=)
AU (1) AU2008305303A1 (https=)
CA (1) CA2699773A1 (https=)
IL (1) IL204728A0 (https=)
WO (1) WO2009042444A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051244A1 (ja) 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
US8853215B2 (en) 2009-04-16 2014-10-07 Takeda Pharmaceutical Company Limited Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
JP5951625B2 (ja) * 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
WO2012074038A1 (ja) * 2010-12-02 2012-06-07 第一三共株式会社 修飾１本鎖ポリヌクレオチド
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
US9944596B2 (en) * 2014-10-24 2018-04-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102490156B1 (ko) 2014-10-24 2023-01-18 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
AU2021265838A1 (en) * 2020-04-29 2022-10-20 Saliogen Therapeutics, Inc. Compositions and methods for treatment of inherited macular degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Also Published As

Publication number Publication date
IL204728A0 (en) 2010-11-30
WO2009042444A2 (en) 2009-04-02
KR20100097098A (ko) 2010-09-02
CA2699773A1 (en) 2009-04-02
CN101873852A (zh) 2010-10-27
EP2205234A4 (en) 2010-12-22
JP2010540541A (ja) 2010-12-24
WO2009042444A3 (en) 2009-05-14
EP2205234A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
US7973079B2 (en) Methods and compounds for treating retinol-related diseases
AU2008305303A1 (en) Methods and compounds for treating retinol-related diseases
US8314152B2 (en) Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20120288568A1 (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation
JP2008515778A (ja) 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
HK1122744B (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation
HK1107671B (en) Methods and compositions for treating ophthalmic conditions with retinyl derivatives

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: REVISION THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): SIRION THERAPEUTICS, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application